Atara Biotherapeutics, Inc. (ATRA)
Pre-market:
- Business Wire
Atara Biotherapeutics Submits Tabelecleucel (Tab-cel®) Biologics License Application for Treatment of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease with U.S. FDA
THOUSAND OAKS, Calif., May 20, 2024--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced that Atara has submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for tabelecleucel (tab-cel®) indicated as monotherapy for treatment of adult and pediatric patients
- Simply Wall St.
Atara Biotherapeutics First Quarter 2024 Earnings: Beats Expectations
Atara Biotherapeutics ( NASDAQ:ATRA ) First Quarter 2024 Results Key Financial Results Revenue: US$27.4m (up by...
- Zacks
Atara Biotherapeutics (ATRA) Reports Q1 Loss, Tops Revenue Estimates
Atara Biotherapeutics (ATRA) delivered earnings and revenue surprises of 37.84% and 1.32%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
